For instance, HER2-targeting peptides have been reported to interfere with receptor dimerization and attenuate PI3K/Akt signaling, yielding antiproliferative effects in HER2-overexpressing breast cancer models [140,141]. This evidence concerns the gene ERBB2 and breast carcinoma.